I'm thrilled to share great news with you all. For the treatment of Wolman disease, the National Institute for Health and Care Excellence (NICE) has advised the NHS to employ sebelipase alfa, an enzyme replacement therapy (ERT). Hashir Nawaz, an eight-year-old from Sheffield who began receiving therapy with sebelipase alfa in January 2016 as part of a clinical trial at the NIHR Manchester CRF, has received life-saving care from the Manchester team.

After reading this, you may be interested in learning more about ERT. Using recombinant DNA technology, certain enzymes are extracted from cells and given to patients regularly to treat reduced enzyme function, which is the basis of ERT. It's a subtype of protein therapy in which the protein functions as an enzyme. Learn about the complex mechanisms underlying ERT and its significant effects on hereditary disease treatment and enzyme deficits. Explore how this cutting-edge medical strategy transforms alternatives to therapy and enhances the quality of life for those who suffer from rare illnesses.

Introduction

A hereditary enzyme deficiency syndrome patient usually receives ERT to replace a missing or insufficient enzyme. An enzyme isolated from human, animal tissue or blood, created using cutting-edge recombinant techniques, is infused in place of the absent enzyme. An extended half-life, increased potency, resistance to degradation, or targeting of a particular organ, tissue, or cell type are the most common modifications made to the enzyme.

Alpha-1-antitrypsin (A1AT) deficiency received ERTs for the first time successfully in history utilising purified human A1AT obtained from plasma. A second effective ERT variation emerged for Gaucher disease—a hereditary impairment of lysosomal acid β-glucocerebrosidase that causes the substrate to accumulate in lysosomes. 

Forty years ago, Christian de Duve presented the idea of ERT for lysosomal storage diseases (LSD), briefly explaining it as follows: We should bear in mind that any material that enters cells through the endocytic process will most likely wind up inside lysosomes when making assumptions about pathogenicity and trying to find treatments. It creates a plethora of opportunities for communication, including substitute treatment. The idea of LSD was novel at the time, having only been put forth by Hers and associates following the identification of acid maltase deficiency as the cause of Pompe disease.

However, the relationship between endocytosis and lysosomes was well established. The efficiency of using invertase to hydrolyse sucrose in liver lysosomes in vivo or in vitro in lysosomes of cultured macrophages provided experimental support for ERT.^1,2

Understanding enzyme deficiency diseases

A buildup of toxic compounds that might impair regular organ functions and prevent the production of essential biological chemicals and other intermediates is the outcome of metabolic enzyme deficiency (MED), also known as enzyme deficiency. The problems associated with MED encompass several clinical manifestations and can affect nearly every organ system. MED could be an inborn error of metabolism (IEM) group of illnesses caused by a single gene deficiency that prevents some essential steps in the regular metabolic pathway, resulting in insufficient product or substrate deposition for normal organ functions. "Loss-of-function" mutations are assumed to be the hereditary cause of enzyme deficiency.

Both autosomal recessive inheritance—wherein parents contain a defective gene and pass it on to the child—and X-linked recessive inheritance—wherein only the mother carries the damaged gene on the X chromosome and passes it on to the child—are possible inheritance patterns for this. Interrupted biochemical responses are a concern linked to acquired. Some complications associated with different MED disorders include myositis, anaemia, pulmonary valve stenosis (PVS), inflammatory bowel disease (IBD), splenomegaly, short stature, hepatomegaly, vomiting, drowsiness, hypotonia and seizures.³

Mechanisms of ERT

The flowchart explains how ERT works.

Therapies based on enzymes can be systemic or non-systemic, and they have multiple administration routes: oral, topical, respiratory and intravenous (IV). Significant therapeutic benefits from IV infusions include improved breathing, better walking abilities and quality of life. Development of different methods to overcome the limited access of enzymes into challenging pathological sites include-

• Boosting the expression rate of M6P receptors or residues on the target cells to the recombinant enzyme can increase the cellular uptake of the enzyme through an active targeting mechanism- based on the receptor-mediated lysosomal enzyme delivery system (EDS)
• Enzyme-loaded nanosystems (ENSs) with cutting-edge nano biomaterials to maximise ERT's effectiveness and reduce its adverse effects. Nanoscaled EDSs use an array of nanocarriers such as polymer- and lipid-based nanoparticles, biodegradable nano micelles, and nanoliposomes
• Polymeric/lipidic nanoparticles are an additional way to pass biological barriers like the blood-brain barrier (BBB) and blood-ocular barrier (BOB) when coated with agents (such as aptamers or antibodies)^6,7

Types of ERT and indications

The table lists various ERT types and diseases they treat.

Efficacy and clinical outcomes

Improvement in symptoms and quality of life

The real-world setting and clinical trial results validate the safety and effectiveness of ERT in treating complex multisystem, progressive illnesses. ERT reduces GAG (urinary glycosaminoglycan) and increases the size of the liver and spleen. It enhances the heart muscle's contraction and geometry.

ERT somewhat increases lung function, while individual differences in improvement are significant. After ERT, some patients experienced improvements in photophobia, visual acuity, and other eye issues; however, most patients do not show these improvements. ERT helps enhance activities of daily living (ADL), health-related quality of life (HRQoL), and pain in those patients with no cognitive delay.⁴

Long-term effects on disease progression

Treatment adherence, the severity of the illness, the time of beginning, and the existence of concurrent conditions impact the long-term efficacy of ERT. For instance, the most significant indicators of the long-term result of ERT in Fabry disease are age, sex, and phenotype. Patients with cardiac fibrosis, proteinuria, and reduced renal function can't benefit similarly from ERT. Even though people without significant organ involvement might also experience disease progression, therapy before the development of irreversible organ damage may result in better outcomes.⁹

Challenges and limitations

Numerous challenges and limitations surround ERT, affecting its general efficacy and usability. Even while several methods serve to address some of the challenges, such as distribution to challenging pathological areas as covered in my article's mechanism of ERT section, these strategies are unsuccessful for different LSD forms. The issues associated with ERT appear in the schematic illustration below.⁷

Safety considerations

ERT for MPS has a well-tolerated safety profile. A reported 50% of MPS I patients treated with Laronidase, 30% of MPS II patients treated with Idursulphase, 90% of MPS IVA patients treated with Elosulphase, and 50% of MPS VI patients receiving Galsulphase reported angioedema, rhinitis, rash, urticaria, bronchoconstriction, and anaphylaxis examples of infusion adverse reactions (IAR). Desensitisation is recommended in the event of recurring IARs when pre-medication fails to stop hypersensitive reactions. Patients undergoing ERT encounter symptoms of the illness and the advantages and disadvantages of the treatment.

The psychological component investigates how individuals view their day-to-day experiences with the disease, adjusting to the ERT regimen, the emotional toll, cognitive processes, decision-making, and coping mechanisms. In the social domain, communication and relationships examine how the condition and its treatment affect interpersonal connections. Patient education and counselling encourage open conversation, mutual trust, and cooperation between patients, carers, and medical professionals. It helps to create a supportive care environment that improves the quality of life and treatment outcomes for those receiving ERT.^4,10 

FAQs

What is the duration of ERT?

Every infusion for ERT requires three to four hours, according to the enzyme and dosage. ERT is a lifelong therapy. Severe infusion responses could occur; this risk makes most infusions administered in a hospital setting; however, some individuals can receive infusions safely and effectively at home.⁴

How much does ERT cost?

ERT can be expensive. The complicated manufacturing procedures needed to produce recombinant enzymes are the primary cause of the high cost. The cost of ERT is close to $200,000 annually. Insurance plans, government subsidies, financial aid, or reimbursement support all help to lower ERT costs.⁵

What steps are involved in the ERT's development and approval process?

ERT involves a lengthy and costly procedure in academic laboratories before being transferred to pharmaceutical companies. The generalised ERT development process appears in the picture.

What are the future perspectives of ERT?

Creative biotechnology approaches are underway to address the limitations of enzyme medicines. Furthermore, conjugations with biomolecules like antibodies, DNA, or metabolites are under scrutiny, and polyethylene glycol-conjugated (PEG) alterations are employed in therapy to improve the properties of enzymes by molecular modification. Simultaneously, new methods of applying enzyme treatment remain evaluated for joint issues, infections, neurological illnesses, cancer, and inflammation. Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the virus that causes COVID-19, has also been treated using enzymes as therapies.⁶

Summary

• ERT is a novel medicinal intervention used to treat illnesses caused by enzyme deficiencies
• By adding exogenous enzymes to the body to replace the ones lacking, ERT helps restore normal metabolic function, reducing symptoms and enhancing the quality of life for those who suffer from enzyme deficiency illnesses
• Treating LSDs, metabolic diseases, and other uncommon genetic problems is where ERT excels
• Physicians enable patients to make knowledgeable decisions about their treatment and effectively manage their conditions by giving accurate, thorough information about ERT